Trial Search Results

Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner syndrome) or medical therapies. We hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: 17beta Estradiol
  • Drug: Conjugated estrogens
  • Drug: 17Beta Estradiol - transdermal
  • Drug: Progesterone, micronized




Inclusion Criteria: in whom initiation of estrogen therapy has been recommended due to
ovarian failure

   - Outpatients

   - age >=12 years to 17.99 years old

Exclusion Criteria:

   - spontaneous menses

   - significant concurrent medical problem including:

   - Liver function tests (LFTs) 3 times normal

   - clotting disorder

   - ongoing cancer treatment

Ages Eligible for Study

12 Years - 18 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sejal Shah